GSK plc 6-K, filed Nov 5, 2021
GSK plc (GSK)
6-K
2021-11-05
For: 2021-11-05
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on November 5, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 5 November 2021, London UK
GSK announces positive Phase III efficacy
and safety data for daprodustat in patients with anaemia due to
chronic kidney disease
●
Late-breaking
data from the daprodustat ASCEND-ND and ASCEND-D trials at the
American Society of Nephrology's Kidney Week 2021 confirms the
potential for a new oral treatment for
patients
with anaemia due to chronic kidney disease in both
non-dialysis and dialysis
settings
● Data from five Phase III studies demonstrated that
daprodustat improved or maintained haemoglobin within target
levels, without increased cardiovascular risk when compared to
standard of care
● Pivotal trials in non-dialysis and dialysis
populations published simultaneously in
the New
England Journal of Medicine
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive
results from the Phase III ASCEND (Anaemia Studies in Chronic
Kidney Disease: Erythropoiesis via a novel prolyl hydroxylase
inhibitor Daprodustat) programme for daprodustat, an
investigational oral hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), during a presentation at the American Society
of Nephrology's Kidney Week 2021. The positive primary efficacy and
safety results confirm the potential for daprodustat to be a new
oral treatment for patients with anaemia due to chronic kidney
disease (CKD) in both non-dialysis and dialysis settings.
Daprodustat was developed based upon the unique Nobel Prize-winning
science that demonstrated how cells sense and adapt to oxygen
availability.
The ASCEND programme is comprised of five Phase III studies
assessing the efficacy and safety of daprodustat for the treatment
of anaemia due to CKD across the CKD disease course. The programme
enrolled over 8,000 patients who were treated for up to 4.26 years.
Daprodustat was well tolerated in both non-dialysis and dialysis
populations as assessed in the primary analysis. Data on
daprodustat, including results from the two pivotal Phase III
studies focused on non-dialysis (ASCEND-ND) and dialysis (ASCEND-D)
patients, were shared at the American Society of Nephrology's
meeting in a combined late-breaking oral presentation. Results for
ASCEND-ND and ASCEND-D were also published simultaneously in
the New England Journal of
Medicine.
The ASCEND-ND and ASCEND-D studies each independently met their
primary efficacy and safety endpoints. Efficacy results from both
Phase III studies demonstrated that daprodustat improved or
maintained patients within their target haemoglobin (Hb) range. In
addition, results from the prespecified primary safety analysis of
the intention-to-treat (ITT) population showed similar
rates of major adverse cardiovascular events (MACE), defined
as all-cause mortality, non-fatal myocardial infarction, or
non-fatal stroke independently within each trial. In the
ASCEND-ND trial, results showed a hazard ratio reflecting time to
first occurrence of MACE of 1.03; 95% CI, (0.89 to 1.19), achieving
non-inferiority with the pre-defined margin of 1.25. In the
ASCEND-D trial, results showed a hazard ratio reflecting time to
first occurrence of MACE of 0.93; 95% CI, (0.81-1.07), achieving
non-inferiority with the pre-defined margin of 1.25. The outcomes
in each study and across treatment arms confirmed no
increased cardiovascular risk for daprodustat compared to
an erythropoietin stimulating agent (ESA), the current standard of
care.
The most commonly reported adverse events in patients receiving
daprodustat included hypertension, diarrhoea, dialysis hypotension,
peripheral oedema and urinary tract infection.
Daprodustat is the first oral HIF-PHI to clearly show positive
efficacy, along with no increased cardiovascular risk as assessed
in the primary analysis of MACE in the ITT population compared to
an ESA, across both non-dialysis patients and dialysis
patients.
Dr. Hal Barron, Chief Scientific Officer and President
R&D, GSK, said,
"Over 700 million people suffer from chronic kidney disease
worldwide, and an estimated 1-in-7 of these patients suffers from
anaemia. Grounded in research based on Nobel Prize-winning science,
we believe these data show daprodustat has the potential to
transform the treatment landscape for these patients, many of whom
have limited treatment options today."
In addition to the primary analysis of the ITT population, several
additional supplementary analyses were performed for both ASCEND-ND
and ASCEND-D trials. Further details can be found in
the New England Journal of
Medicine publication.
Data from three additional trials within the ASCEND programme
provided further support for the use of daprodustat. The ASCEND-TD
trial showed positive efficacy results for three-times weekly
dosing, in addition to the once-daily dosing regimen evaluated in
ASCEND-ND and ASCEND-D studies, providing data to support
additional dosing options for daprodustat. Additional results
demonstrated treatment with daprodustat led to significant
improvement compared to placebo in non-dialysis dependent patients'
Hb levels and quality of life by measure of SF-36 vitality score
(as determined by level of fatigue) in the ASCEND-NHQ trial, as
well as the ability to maintain Hb levels in the high-risk incident
dialysis population in the ASCEND-ID trial.
Dr. Ajay Singh, nephrologist/principal
investigator and Chair of Executive Steering Committee and Steering
Committee for the ASCEND Programme and Senior Associate Dean for
Postgraduate Medical Education, Harvard Medical
School said, "As a
nephrologist who regularly treats patients with anaemia due to
chronic kidney disease, I think these are ground-breaking results
and show that daprodustat has potential to be transformative for
these patients. The ASCEND programme was designed to represent
anaemia management in practice today, and these results provide
strong clinical evidence to help nephrologists as they make the
right treatment decisions for their patients."
Sir Peter J. Ratcliffe, Professor of Medicine, University of
Oxford, Francis Crick Institute and Nobel
laureate said, "Derived
from decades of research investigating how the cells sense and
adapt to oxygen availability, it's extraordinary to see how this
work has been translated into positive clinical evidence within the
ASCEND programme. The data shared today demonstrate the importance
of following the science and how better understanding the body's
natural responses enables us to create medicines that can have a
meaningful impact on patients' lives."
Daprodustat is currently approved in Japan as Duvroq for patients
with renal anaemia. It is not approved anywhere else in the world.
The results from the Phase III ASCEND programme will be used to
support regulatory filings with health authorities
worldwide.
Notes to editors:
Results from the ASCEND-ND and ASCEND-D trials
● ASCEND-ND (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Non-Dialysis) enrolled 3,872 non-dialysis
dependent patients with anaemia associated with CKD who were either
switched from standard of care (ESA) or not currently receiving ESA
therapy to receive daprodustat or ESA control (darbepoetin alfa).
Iron management protocols were instituted across both arms in the
study. The study met its primary safety and efficacy endpoints.
Results showed daprodustat improved and/or maintained Hb within
target level (10-11.5 g/dL) for these patients, and the primary
safety analysis of the ITT population showed that daprodustat
achieved non-inferiority compared to ESA
control.
● ASCEND-D (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Dialysis) enrolled 2,964 dialysis patients with anaemia
associated with CKD who were switched to receive daprodustat
or ESA control from a standard of care ESA therapy. A uniform iron
management protocol was instituted across both arms of the study.
The study met its primary safety and efficacy endpoints. Results
showed daprodustat improved or maintained Hb within target levels
(10-11.5 g/dL) for these patients, and the primary safety analysis
of the ITT population showed that daprodustat achieved
non-inferiority compared to ESA control.
About anaemia due to CKD
Chronic kidney disease (CKD), characterised by progressive loss of
kidney function, is an increasing global public health burden. Risk
factors for CKD include hypertension, diabetes, obesity and primary
renal disorders. Furthermore, CKD is an independent risk factor for
cardiovascular disease.i Anaemia
is an important and frequent complication of CKD. However, it is
often poorly diagnosed and undertreated in patients with
early-stage CKD, such as those not on dialysis. When left untreated
or undertreated, anaemia due to CKD is associated with poor
clinical outcomes and leads to a substantial burden on patients and
healthcare systems.
About daprodustat
Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), belongs to a novel class of oral medicines
indicated for the treatment of anaemia due to chronic kidney
disease (CKD) in adult patients not on dialysis and on
dialysis. Inhibition of oxygen-sensing prolyl hydroxylase enzymes
stabilises hypoxia-inducible factors, which can lead to
transcription of erythropoietin and other genes involved in the
correction of anaemia, similar to the physiological effects that
occur in the body at high altitude. Daprodustat has been developed
to provide a convenient oral treatment option for patients with
anaemia associated with CKD.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary
statement regarding forward-looking statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described in the Company's Annual Report on Form
20-F for 2020, GSK's Q3 Results and any impacts of the COVID-19
pandemic.
Registered
in England & Wales:
No.
3888792
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
05, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|